Enanta Pharmaceuticals Inc <ENTA.OQ> expected to post a loss of $1.28 a share - Earnings Preview

• Enanta Pharmaceuticals Inc ENTA.OQ ENTA.O is expected to show a fall in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025

• The Watertown Massachusetts-based company is expected to report a 13.5% decrease in revenue to $15.539 million from $17.97 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Enanta Pharmaceuticals Inc is for a loss of $1.28 per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 62.1% above its last closing price of $7.58

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated August 1 at 11:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)